| abstract |
The present invention relates generally to antigen-specific tolerogenic protein therapy and its use to treat adverse immune responses, such as those associated with autoimmune diseases such as multiple sclerosis (MS) and hemophilia. In particular, the present invention includes the application of B cell targeted IgG fusion proteins as antigen specific tolerogenic protein therapies alone or in combination with inhibitory antibodies. The fusion protein comprises a B cell specific targeting module, a human IgG4 heavy chain constant region or fragment thereof, and an antigen. [Selection] Figure 2B |